Investment Rating - The report does not explicitly state the investment rating for Innovent Biologics (1801 HK) Core Insights - Innovent Biologics showcased multiple clinical data at the 2024 ASCO Annual Meeting, highlighting its R&D capabilities with various monoclonal antibodies, bispecific antibodies, and ADCs [3][8] - IBI363 demonstrated promising safety and efficacy in treating cold tumors and IO-resistant tumors, particularly in advanced colorectal cancer patients with a median of ≥3 prior treatment lines [4][9] - IBI389 and IBI343 are positioned well in the market, with IBI389 showing lower treatment-related adverse events compared to standard chemotherapy in pancreatic cancer [4][10] - New data from IBI310 combined with sintilimab indicates significant improvements in pathological complete response rates in MSI-H/dMMR CRC patients [10] Summary by Sections Clinical Data Highlights - In May 2024, Innovent Biologics released clinical data for IBI363, IBI389, IBI343, and IBI310 at ASCO 2024 [3][8] - IBI363 showed good response rates and disease control rates in advanced colorectal cancer, particularly in patients with PD-L1 CPS≥1 [4][9] - IBI389 demonstrated a lower incidence of grade 3 and above treatment-related adverse events compared to standard chemotherapy in advanced pancreatic ductal adenocarcinoma [10] Efficacy and Safety - IBI363 exhibited overall acceptable tolerability and manageable safety, with a lower incidence of grade 3 and above treatment-related adverse events compared to PD-1/PD-L1 therapies [4][9] - IBI343 achieved a notable overall response rate of 40% in a subgroup of pancreatic cancer patients with CLDN18.2 expression ≥60% [5][10] - The combination of IBI310 with sintilimab significantly increased the pathological complete response rate compared to sintilimab monotherapy in CRC patients [10]
信达生物：2024 ASCO：多项临床数据公布，彰显公司研发实力